Does CHA2DS2-VASc score predict mortality in chronic kidney disease?

Intern Emerg Med. 2021 Oct;16(7):1737-1742. doi: 10.1007/s11739-021-02799-5. Epub 2021 Jul 7.

Abstract

Chronic kidney disease (CKD) is a leading cause of morbidity and mortality worldwide. Assessment of cardiovascular (CV) and all-cause mortality in CKD patients is of particular importance. CHA2DS2-VASc (congestive heart failure, hypertension, age ≥ 75 years, diabetes, prior stroke, vascular disease, age 65-74 years, and sex) score was originally formulated to predict the annual thromboembolic risk in patients with nonvalvular atrial fibrillation (AF). The calculation of R2CHADS2 and R2CHA2DS2VASc scores awarded an additional 2 points for CrCl < 60 mL/min and GFR < 60 mL/min/1.73 m2. Recent studies have investigated whether CHA2DS2-VASc and R2CHADS ± VASC scores could be used to predict CV or all-cause mortality in patients with CKD. CHA2DS2-VASc score was proven to be a significant predictor of CV and all-cause mortality in CKD patients, and a higher CHA2DS2-VASc score was associated with increased mortality. These findings are quite promising, and they may help physicians to identify high-risk groups in this population.

Keywords: CHA2DS2-VASc; Chronic kidney disease; Mortality.

MeSH terms

  • Atrial Fibrillation
  • Forecasting
  • Heart Failure
  • Humans
  • Hypertension
  • Renal Insufficiency, Chronic / mortality*
  • Risk Assessment / methods*
  • Sex Factors
  • Stroke